ChinaDrugStatus

Pamiparib

帕米帕利
Brand: Partruvix / 百汇泽·Oncology·Last verified 2026-11-20

PARP inhibitor not renewed in the 2026 NRDL adjustment; explicitly granted a 6-month transition period under original payment terms through June 30, 2027.

China Approval (NMPA)

Approved
Approval Number(s)
国药准字H20210016
Initial Approval Date
May 7, 2021
Notice Published
May 7, 2021
MAH
BeiGene (Suzhou) Co., Ltd. (百济神州(苏州)生物科技有限公司)
Approved Scope
Conditional approval for patients with gBRCA-mutated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer after two or more prior lines of chemotherapy.

National Reimbursement

Announced · Effective Jan 1, 2027
2026 Adjustment
Removed from 2026 NRDL (non-renewed negotiated drug)
Transition Clause
Original payment standard continues through Jun 30, 2027
Prior 2025 Listing
2025 NRDL #256 (Class B) — Restricted to patients with gBRCA-mutated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer after ≥2 prior lines of chemotherapy.

Commercial Insurance List

Not Listed

Not listed in the 2025 or 2026 NHSA Commercial Health Insurance Innovative Drug List.

Approved Products, Dosage Forms & Approval Numbers

1 verified NMPA record
Approval No.Dosage Form & StrengthEvent & ScopeApproval / Notice DateMAH & Source
国药准字H20210016
Capsule (胶囊剂)
20mg
Initial Approval

Conditional approval for patients with gBRCA-mutated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer after two or more prior lines of chemotherapy.

附条件批准用于既往经过二线及以上化疗的伴有胚系BRCA(gBRCA)突变的复发性晚期卵巢癌、输卵管癌或原发性腹膜癌患者。

Approved: 2021-05-07
Published: 2021-05-07
BeiGene (Suzhou) Co., Ltd.

Change Timeline

  1. (2027-06-30)Transition Clause· Notice published: Nov 14, 2026

    6-Month Transition Period Ends

    Original negotiated payment standard remains reimbursable through June 30, 2027 per the 2026 NHSA notice.

    Chinese original: 未成功续约调出谈判药品给予6个月过渡期,2027年6月底前医保基金可按原支付标准继续支付。

  2. (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026

    2026 NRDL · Removed from Negotiated List

    Removed from 2026 NRDL after unsuccessful renewal (was 2025 Negotiated #256); 6-month transition period under original payment standard runs through Jun 30, 2027.

    Chinese original: 未成功续约调出2026版目录(原2025版谈判第256项);通知明确给予6个月过渡期,2027年6月30日前可按原支付标准继续支付。

  3. (2021-05-07)NMPA Approval

    NMPA Initial Marketing Approval (国药准字H20210016 · 20mg)

    Conditional approval for patients with gBRCA-mutated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer after two or more prior lines of chemotherapy.

    Chinese original: 附条件批准用于既往经过二线及以上化疗的伴有胚系BRCA(gBRCA)突变的复发性晚期卵巢癌、输卵管癌或原发性腹膜癌患者。

Verified Names & Aliases

Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.

帕米帕利胶囊dosage name(NHSA)
BGB-290code(WHO)
百汇泽brand zh(NMPA)

Primary Sources for This Record